Skip to main content
  1. Home
  2. Emerging Tech
  3. News

FAA relaxes certain drone regulations, letting quadcopters fly higher

Add as a preferred source on Google

The sky really is becoming the limit for drones these days. Turning just about everyone into a pilot of some sort, these quadcopters have gained considerable popularity in the last several months, and are now gaining altitude as well. Thanks to newly relaxed rules announced by the Federal Aviation Association (FAA), both commercial and government drones will be allowed to fly up to 400 feet in the air, double the previous limit of 200 feet.

“Expanding the authorized airspace for these operations means government and industry can carry out unmanned aircraft missions more quickly and with less red tape,” FAA Administration Michael Huerta said in a statement. A word to the wise, however — operators will only be able to take advantage of this new, higher limit if they apply for a waiver from the FAA.

Recommended Videos

“The FAA’s decision to raise the operating altitude of the blanket COA from 200 feet to 400 feet provides greater flexibility to those receiving FAA exemptions and makes it easier for more commercial UAS operators to access the skies,” said Brian Wynne, president and CEO of the Association for Unmanned Vehicle Systems International, an advocacy group for both the drone and robotics industries. Of course, drones and their operators would still like to go higher, but the rule that would increase the ceiling to 500 feet has yet to be fully approved.

While this certainly marks a step forward for drone enthusiasts, there remain a number of obstacles to the full enjoyment of quadcopters across the country. You still can’t fly at night, you must keep your drone within your sight, and you must stay far, far away from airports and other restricted areas. That said, the FAA also just made it easier to register your drone online, and this will cost owners just $5 (the same price as model airplane registration).

So fly high, drone lovers. Slowly but surely, the rules seem to be changing in your favor.

Lulu Chang
Fascinated by the effects of technology on human interaction, Lulu believes that if her parents can use your new app…
Students who use AI every day may be falling behind, while moderate users pull ahead
New global testing data suggests more AI in the classroom isn't automatically better.
Logo, Text

I assumed more AI access might help students learn faster. However, a new OECD study dispels that misconception for me and everyone else who gave their children a paid version of AI chatbots, thinking it would help them through their educational journey. 

According to PISA 2025 data from 760,000 students in 91 countries, students who use AI daily score meaningfully worse on standardized tests than their peers. The full picture is more complicated than a simple ban would fix.

Read more
XPENG just put its humanoid robot on the production line, and it walked itself out
IRON clocks in for its first shift
XPENG Iron

XPENG’s humanoid robot has officially joined the workforce, and it even got an employee badge. The Chinese automaker announced on September 8 that its next-generation IRON had completed assembly and autonomously walked off its newly commissioned humanoid robot production line in Guangzhou.

CEO He Xiaopeng then pinned a staff badge onto the robot, symbolically welcoming it to the XPENG team. It is a charming little ceremony for a machine that the company hopes will eventually become a regular part of everyday life. XPENG is moving IRON beyond R&D prototypes toward production-line manufacturing, applying the quality-control systems and manufacturing experience it has developed through its electric vehicle business.

Read more
An AI-designed drug might help slow aging, but we’re not there yet
The results hint at a possible anti-aging effect, but there’s still a long way to go before we know what it means.
medical test tubes

Rentosertib, a drug Insilico Medicine designed almost entirely using AI, was created to treat idiopathic pulmonary fibrosis, a disease that scars and stiffens the lungs over time. But fighting lung disease was only half the plan from the start.

According to a new study published in Nature Biotechnology, the drug's target was chosen specifically because it overlaps heavily with the biology of aging, and the whole trial was designed to test whether treating the lungs could also mean turning back the body's biological clock.

Read more